Abstract: 39 patients were treated by supporting theraphy alone and supporting theraphy plus high dose .Tiandicin from October,1996 to March 1997. Results :The median survial period and the rate for impovement of appetite were 15.4 weeks and 45%(9/20) in combination theraphy group and 7.79 weeks and 0%in supporting theraphy alone group (P<0.01). Conclusion :Using high dose Tiandicin and supporting theraphy will not only lengthen the lifetime of the terminal cancerous patients but also improve the quality of life.